Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


Revenue 2017


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. MabThera/Rituxan was produced by Roche.

Deal Watch November 2016

Deal Watch November 2016 We are starting to see more deals covering biosimilars and this month Poland-based Mabion signed a supply and commercialisation agreement with Mylan for a biosimilar of Roche's ... competitors. The patents covering MabThera/Rituxan expired in Europe in

Genentech names Anderson new CEO as Ian Clark retires

Genentech names Anderson new CEO as Ian Clark retires Big-selling brands such as breast cancer therapy Herceptin (trastuzumab), Avastin (bevacizumab) for solid tumours and MabThera/Rituxan (rituximab) for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are

Deal Watch October 2016

Deal Watch October 2016 Teva has paid $160m upfront with $60m refundable or creditable (presumably if registration fails) for rituximab (Rituxan) and trastuzumab (Herceptin), both in late phase III development.

Roche in "unprecedented" launch period for new medicines

Roche in Two of Roche's other big sellers - MabThera/Rituxan (rituximab) and Avastin (bevacizumab) - managed to grow slightly despite competition and pricing pressure. ... Avastin is already facing biosimilar competition in some emerging markets and MabThera

AbbVie and Roche's leukaemia drug venetoclax nears EU market

AbbVie and Roche's leukaemia drug venetoclax nears EU market It is also being tested in combination with Roche's $7bn brand MabThera/Rituxan (rituximab), which is widely-used for CLL, as well as Imbruvica which also cleared $1.2bn in

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts


Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...
2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....